Mount Yale Investment Advisors’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY.RT
PCM
ACM
FCM
BFS
LGP
CS
LCM
NCM
Mount Yale Investment Advisors's BMY.RT Position: Q4 2020 in Review
Mount Yale Investment Advisors sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q4 2020, closing a stake of 106,905 shares — an estimated $241K sold.
Mount Yale Investment Advisors first reported a position in BMY.RT in Q4 2019 and held it in 4 quarters. The position peaked at $408K in Q1 2020. 546 funds tracked by Wall St. Rank hold BMY.RT as of Q4 2020.
- Mount Yale Investment Advisors reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q4 2020 after selling out during the quarter.
- Mount Yale Investment Advisors sold 106,905 Bristol-Myers Squibb Company Contingent Value Rights shares in Q4 2020, an estimated $241K.
- Mount Yale Investment Advisors first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 4 quarters.
- Mount Yale Investment Advisors's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $408K in Q1 2020.
- 546 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q4 2020.
Based on Mount Yale Investment Advisors's 13F filing for Q4 2020, filed 12 Feb 2021.